Published in Cancer Weekly, January 16th, 2007
MCL is a relatively uncommon and aggressive form of non-Hodgkin lymphoma for which there was no standard of care in the relapsed or refractory setting. MCL has a U.S. prevalence of 10,000 patients. Velcade is currently the market leader in multiple myeloma (MM) for patients who have received one prior therapy. This approval marks the first indication for Velcade in lymphoma, the most common blood cancer.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.